control. Since the delta Ct's can be discriminated, the assay showed a positive feasibility of using a cfDNA in the Q-Clamp ® KRAS codon specific mutation test.
Objectives
1. Describe KRAS, the specific codons it mutates, and its pathways.
2. Describe the mechanics of the assay, how it works, and its intended use.
3. Describe cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA). To my family and friends, who in one way or another shared their support and encouragement which helped me in completion of this paper, thank you.
But on top of all these, to the Great Almighty, the author of knowledge and wisdom, for His countless love.
Thank you.
Manuel Mina Garcia xi I. INTRODUCTION

A. KRAS
KRAS is a proto-oncogene which was first identified in Kirsten rat sarcoma virus (Tsuchida, et al., 1982 gene-mutation-detection-kits-2/kras-mutation-test).
The validated instruments and product specification are shown in To reduce the wild-type background and improve sensitivity, a molecular clamp has been designed to hybridize selectively to wild-type template DNA and block its amplification. This molecular clamp consists of a synthetic, sequence-specific Xeno-nucleic acid (XNA) probe. In the presence of a mutation such as a single nucleotide polymorphism (SNP) gene deletion, insertion, or rearrangement in the region of the XNA probe sequence, the XNA probe molecule melts off the mutant template DNA during the PCR cycling process, and only mutant templates are amplified efficiently (Q-Clamp ® Kras codon specific mutation test instruction manual). 
E. Cell-Free
Purpose
This experiment was performed to test if the limit of detection could go low enough using cfDNA in an assay kit designed and optimized using FFPE extracted DNA and genomic DNA references.
Q-Clamp ® Workflow:
The assay workflow consists of four (4) 
B. Set Up qPCR
Samples used are Reference Standard (mutant DNA), Diluent (wild type DNA); both are cell-free DNA.
The assay was set up by serially diluting 5 ng (2uL) of the 5% mutant cfDNA standard reference with 5 ng of the wild type cfDNA (2uL) at 0.5, 0.25, 0.125 and 0.0625 dilutions. Two µL of this mixture from these dilutions was added to the reaction plate. Each sample and control was run in duplicate.
The PCR reactions are set up in a total volume of 10 μL/reaction as shown in Table 2 Nuclease-Free Water is used in the place of template. The NTC serves as a negative control and assesses potential contamination during assay set-up.
C. Enter Amplification Parameters
Eight uL of the mixture (PCR master mix, PPM, XNA, and water) was transferred to each well in a 384-well plate using a multichannel pipette as reflected in Table 3 . Analysis is performed using both FAM and HEX channel readings.
The Ct values from these files is used to evaluate the presence or absence of mutations using the Q-Clamp ® KRAS codon specific mutation test user manual.
A cycle threshold (Ct) value for each analyzed sample is generated by the PCR instrument. The Ct is the cycle number at which a signal is detected above the set threshold for fluorescence. The higher the cycle number at which signal is detected, the weaker is the PCR reaction. On the other hand, the lower the cycle number at which signal is detected, the stronger the PCR reaction it represents.
Controls Analysis:
Wild type DNA is used as the template for the mutation negative controls (Clamping Controls). This wild type DNA does not contain the targeted mutations, so the XNA probes will strongly bind to it inhibiting the KRAS amplification. The internal control should amplify to specified amounts though. This will monitor the performance of the primers, polymerase and sample DNA quality and quantity. 12 The positive control template contains mutations, so the XNA probe will not bind to the template allowing the KRAS amplification. Positive controls must show the appropriate value in both HEX and FAM channels to make the run valid.
The no-template controls (NTC) should have no amplification for any of the reactions. Cycle threshold (Ct) should be undetermined.
Mutation Analysis:
The presence or absence of a mutation is determined by the difference codons tested were all within the specified limits in the instruction manual.
III. RESULTS
Codon
As for scoring the mutational status of the codons tested, codon C12 is positive for mutation at 0.5, 0.25, 0.125 and 0.0625 dilutions which means that detection is observed up to 0.3%. Codon C13 is positive for mutation at 0.5, 0.25 and 0.125 dilutions which indicates that the limit of detection with this particular codon is at 0.6%. Codon C59 is positive for mutation at 0.5, 0.25, 0.125 and 0.0625 dilutions so detection is up to 0.3% and with codon C61 the assay was able to detect mutation at 0.25 and 0.0625 dilutions.
Codon C146 had mutation detected at 1.25 and 0.625 dilutions.
With these results, it is observed that three of the five codons (C12, C59 and C61) tested can be detected up to 0.3%. The limit of detection for codon C13 is at 0.6% and C146 at 0.6%. There was no attempt to proceed further dilutions to see how far can possibly detect mutation for C12, C59 and C61 because of unavailability of resources.
The corresponding copy number of mutant DNA is approximately 38 copies for the 2.5% mutation, 19 copies for the 1.25% mutation, 9 copies for the 0.6% mutation and 5 copies for the 0.3% mutation. However, since a clear difference could be distinguished in the delta Ct's between mutation positive (the dilution series) and mutation negative (clamping control/negative control) reactions, it provides the basis for moving forward with continued experiments to further prove the feasibility and optimize the assay for cfDNA use.
